REMARKS/ARGUMENTS

In view of the interview, the claims are further amended as shown above to better differentiate the prior art. The only agreement reached was that the undersigned would submit this further amendment.

Discussion

Sanchez discloses a composition identified as DV-2LD#2 antibody. The composition which this antibody is made against is not fully characterized. However, the DV-2LD#2 antibody is not reactive directly against venom as disclosed at the bottom of page 1454 of Sanchez and the composition discovered by applicant possesses this property. All independent claims are amended above to recite that the anti-LTNF reacts "directly" with the toxin, or at least have the property of being above to do so, to better differentiate this disclosure. The added limitations are submitted to be fairly supported by the specification as filed, especially at the end of Example 4, which states: "Thus, anti-LTNF has the unique property of binding with all tested types of unrelated biological toxins, individually or in mixture," (emphasis in original)

In the language of applicant's specification, Sanchez is bringing together a toxin plus a neutralizing factor to form a complex, and the complex is then reacted with an antibody made against the neutralizing factor for the detection. In order to further differentiate the disclosure of Sanchez on this point, all independent claims are further amended to recite that it is "unneutralized" toxin which reacts with the anti-LTNF. The limitation is submitted to be fairly supported at the end of Example 6 of the specification of filed, wherein it is stated: "The venom neutralized by the specific anti venom is not detected by anti-LTNF."

6

Conclusion

In view of the foregoing, reconsideration and withdrawal of all grounds of rejection and early

notice of allowance is respectfully solicited.

Respectfully Submitted:

Please mail correspondence to:

John R. Casperson

John R. Casperson
PO Box 2174
Friendswood, Texas 77549

Reg. No. 28,198

Tel. No. 281-482-2961

7